Abstract
Caenorhabditis elegans has been proven to be a useful model organism for investigating molecular and cellular aspects of numerous human diseases. More recently, investigators have explored the use of this organism as a tool for drug discovery. Although earlier drug screens were labor-intensive and low in throughput, recent advances in high-throughput liquid workflows, imaging platforms and data analysis software have made C. elegans a viable option for automated high-throughput drug screens. This review will outline the evolution of C. elegans-based drug screening, discuss the inherent challenges of using C. elegans, and highlight recent technological advances that have paved the way for future drug screens.
Original language | English |
---|---|
Pages (from-to) | 247-253 |
Number of pages | 7 |
Journal | Advanced Drug Delivery Reviews |
Volume | 69-70 |
DOIs | |
State | Published - 2014 |
Keywords
- Clozapine (PubChem CID: 2818)
- Drug target identification
- Fluphenazine (PubChem CID: 3372)
- High-throughput screening
- Human disease models
- Nemadipine-A (PubChem CID: 2856102)
- Pharmaceuticals
- Phenotypic analysis
- Small molecules
- Whole organism model